RS57412B1 - Anti-dll3 antitelo - Google Patents
Anti-dll3 antiteloInfo
- Publication number
- RS57412B1 RS57412B1 RS20180696A RSP20180696A RS57412B1 RS 57412 B1 RS57412 B1 RS 57412B1 RS 20180696 A RS20180696 A RS 20180696A RS P20180696 A RSP20180696 A RS P20180696A RS 57412 B1 RS57412 B1 RS 57412B1
- Authority
- RS
- Serbia
- Prior art keywords
- dll3 antibody
- dll3
- antibody
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/30—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants from tumour cells
- C07K16/3023—Lung
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
- C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
- C12Q1/6876—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes
- C12Q1/6883—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material
- C12Q1/6886—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material for cancer
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
- G01N33/574—Immunoassay; Biospecific binding assay; Materials therefor for cancer
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
- C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
- C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
- C07K2317/732—Antibody-dependent cellular cytotoxicity [ADCC]
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
- C07K2317/77—Internalization into the cell
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2319/00—Fusion polypeptide
- C07K2319/30—Non-immunoglobulin-derived peptide or protein having an immunoglobulin constant or Fc region, or a fragment thereof, attached thereto
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q2600/00—Oligonucleotides characterized by their use
- C12Q2600/118—Prognosis of disease development
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
- G01N2333/435—Assays involving biological materials from specific organisms or of a specific nature from animals; from humans
- G01N2333/46—Assays involving biological materials from specific organisms or of a specific nature from animals; from humans from vertebrates
- G01N2333/47—Assays involving proteins of known structure or function as defined in the subgroups
- G01N2333/4701—Details
- G01N2333/4703—Regulators; Modulating activity
Applications Claiming Priority (3)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
JP2010019391 | 2010-01-29 | ||
PCT/JP2011/000485 WO2011093097A1 (ja) | 2010-01-29 | 2011-01-28 | 抗dll3抗体 |
EP11736812.6A EP2530091B1 (en) | 2010-01-29 | 2011-01-28 | Anti-dll3 antibody |
Publications (1)
Publication Number | Publication Date |
---|---|
RS57412B1 true RS57412B1 (sr) | 2018-09-28 |
Family
ID=44319091
Family Applications (2)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
RS20211159A RS62387B1 (sr) | 2010-01-29 | 2011-01-28 | Anti-dll3 antitelo |
RS20180696A RS57412B1 (sr) | 2010-01-29 | 2011-01-28 | Anti-dll3 antitelo |
Family Applications Before (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
RS20211159A RS62387B1 (sr) | 2010-01-29 | 2011-01-28 | Anti-dll3 antitelo |
Country Status (14)
Country | Link |
---|---|
US (3) | US9127071B2 (sr) |
EP (3) | EP3342786B1 (sr) |
JP (1) | JP5918540B2 (sr) |
DK (2) | DK2530091T3 (sr) |
ES (2) | ES2674420T3 (sr) |
HR (2) | HRP20211444T1 (sr) |
HU (2) | HUE056313T2 (sr) |
LT (2) | LT3342786T (sr) |
PL (2) | PL3342786T3 (sr) |
PT (2) | PT2530091T (sr) |
RS (2) | RS62387B1 (sr) |
SI (2) | SI2530091T1 (sr) |
TR (1) | TR201806936T4 (sr) |
WO (1) | WO2011093097A1 (sr) |
Families Citing this family (41)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
AU2009270181B2 (en) * | 2008-07-10 | 2014-05-29 | Toray Industries, Inc. | Pharmaceutical composition for treatment and prevention of cancer |
RS62387B1 (sr) | 2010-01-29 | 2021-10-29 | Chugai Pharmaceutical Co Ltd | Anti-dll3 antitelo |
EP3093293A1 (en) * | 2012-02-24 | 2016-11-16 | Stemcentrx, Inc. | Anti dll3 antibodies and methods of use thereof |
EP2832856A4 (en) * | 2012-03-29 | 2016-01-27 | Chugai Pharmaceutical Co Ltd | ANTI-LAMP5 ANTIBODIES AND USE THEREOF |
GB201302447D0 (en) * | 2013-02-12 | 2013-03-27 | Oxford Biotherapeutics Ltd | Therapeutic and diagnostic target |
SI2958944T1 (sl) | 2013-02-22 | 2019-08-30 | Abb Vie Stemcentrx Llc | Konjugati protiDLL3-protitelo-PBD in njihove uporabe |
US9562099B2 (en) * | 2013-03-14 | 2017-02-07 | Genentech, Inc. | Anti-B7-H4 antibodies and immunoconjugates |
KR20150127199A (ko) | 2013-03-14 | 2015-11-16 | 제넨테크, 인크. | 항-b7-h4 항체 및 면역접합체 |
EP3003390B1 (en) | 2013-06-06 | 2021-07-07 | Pierre Fabre Médicament | Anti-c10orf54 antibodies and uses thereof |
SG11201601375VA (en) * | 2013-08-28 | 2016-03-30 | Stemcentrx Inc | Engineered anti-dll3 conjugates and methods of use |
EP3338793A1 (en) | 2013-08-28 | 2018-06-27 | AbbVie Stemcentrx LLC | Novel sez6 modulators and methods of use |
EP3892294A1 (en) | 2013-08-28 | 2021-10-13 | AbbVie Stemcentrx LLC | Site-specific antibody conjugation methods and compositions |
WO2015038888A1 (en) | 2013-09-13 | 2015-03-19 | Genentech, Inc. | Methods and compositions comprising purified recombinant polypeptides |
RU2016107435A (ru) | 2013-09-13 | 2017-10-18 | Дженентек, Инк. | Композиции и способы обнаружения и количественного определения белка клеток-хозяев в клеточных линиях и рекомбинантные полипептидные продукты |
CN113307873A (zh) | 2013-11-11 | 2021-08-27 | 中外制药株式会社 | 含有改变了抗体可变区的抗原结合分子 |
KR20170008202A (ko) * | 2014-02-21 | 2017-01-23 | 애브비 스템센트알엑스 엘엘씨 | 흑색종에 사용하기 위한 항-dll3 항체 및 약물 접합체 |
CA2956072A1 (en) | 2014-07-21 | 2016-01-28 | Bloodworks | Antibodies that recognize red blood cell antigens |
TW201609812A (zh) | 2014-07-31 | 2016-03-16 | 安美基研究(慕尼黑)公司 | 最佳化之跨物種特異性雙特異性單鏈抗體構築體 |
CN106804108B (zh) | 2014-09-12 | 2021-08-10 | 基因泰克公司 | 抗-b7-h4抗体及免疫缀合物 |
TWI831044B (zh) | 2014-11-11 | 2024-02-01 | 日商中外製藥股份有限公司 | 抗原結合分子、包含抗原結合分子的醫藥組合物以及製造及選擇抗原結合分子之方法 |
MA41613A (fr) * | 2015-02-23 | 2018-01-02 | Abbvie Stemcentrx Llc | Récepteurs antigéniques chimériques anti-dll3 et procédés d'utilisation desdits récepteurs |
TW202346349A (zh) | 2015-07-31 | 2023-12-01 | 德商安美基研究(慕尼黑)公司 | Dll3及cd3抗體構築體 |
ES2776926T3 (es) | 2017-03-29 | 2020-08-03 | Shionogi & Co | Composición medicinal para tratamiento del cáncer |
CN111133005A (zh) | 2017-09-07 | 2020-05-08 | 奥古斯塔大学研究所公司 | 程序性细胞死亡蛋白1抗体 |
CR20200195A (es) | 2017-10-13 | 2020-08-14 | Harpoon Therapeutics Inc | Proteínas de unión a antigenos de maduraciòn de celulas b |
US11952422B2 (en) | 2017-12-05 | 2024-04-09 | Chugai Seiyaku Kabushiki Kaisha | Antigen-binding molecule comprising altered antibody variable region binding CD3 and CD137 |
US11667713B2 (en) | 2017-12-28 | 2023-06-06 | Chugai Seiyaku Kabushiki Kaisha | Cytotoxicity-inducing therapeutic agent |
AU2019267349A1 (en) * | 2018-05-08 | 2020-10-29 | Phanes Therapeutics, Inc. | Anti-DLL3 antibodies and uses thereof |
TW202016151A (zh) | 2018-06-09 | 2020-05-01 | 德商百靈佳殷格翰國際股份有限公司 | 針對癌症治療之多特異性結合蛋白 |
US10815311B2 (en) * | 2018-09-25 | 2020-10-27 | Harpoon Therapeutics, Inc. | DLL3 binding proteins and methods of use |
CA3132202A1 (en) * | 2019-04-08 | 2020-10-15 | Phanes Therapeutics, Inc. | Humanized anti-dll3 chimeric antigen receptors and uses thereof |
US20220281998A1 (en) | 2019-08-28 | 2022-09-08 | Azusapharma Sciences, Inc. | Bifidobacterium spp. expressing and secreting diabody-type bsab |
CN115397866A (zh) | 2020-03-31 | 2022-11-25 | 中外制药株式会社 | 靶向dll3的多特异性抗原结合分子及其用途 |
BR112022017526A2 (pt) | 2020-03-31 | 2022-10-18 | Chugai Pharmaceutical Co Ltd | Método para produzir moléculas de ligação de antígeno multiespecíficas |
EP4217389A1 (en) * | 2020-09-28 | 2023-08-02 | Angitia Biomedicines Limited | Anti-sclerostin constructs and uses thereof |
WO2022153194A1 (en) | 2021-01-13 | 2022-07-21 | Memorial Sloan Kettering Cancer Center | Antibody-pyrrolobenzodiazepine derivative conjugate |
JP2024503658A (ja) | 2021-01-13 | 2024-01-26 | メモリアル スローン-ケタリング キャンサー センター | 抗dll3抗体-薬物コンジュゲート |
WO2023041041A1 (en) * | 2021-09-17 | 2023-03-23 | Wuxi Biologics (Shanghai) Co., Ltd. | D3-binding molecules and uses thereof |
WO2023053272A1 (en) | 2021-09-29 | 2023-04-06 | Chugai Seiyaku Kabushiki Kaisha | Uses of dll3-targeting multispecific antigen-binding molecules |
WO2023092082A1 (en) * | 2021-11-18 | 2023-05-25 | Bentley Cornelia | Antibodies to receptor of advanced glycation end products (rage) and uses thereof |
TW202404647A (zh) * | 2022-07-14 | 2024-02-01 | 大陸商蘇州宜聯生物醫藥有限公司 | 抗體藥物偶聯物及其製備方法和用途 |
Family Cites Families (40)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
GB8607679D0 (en) | 1986-03-27 | 1986-04-30 | Winter G P | Recombinant dna product |
JPS6459878A (en) | 1987-08-31 | 1989-03-07 | Matsushita Electric Ind Co Ltd | Semiconductor laser protective circuit |
DE3920358A1 (de) | 1989-06-22 | 1991-01-17 | Behringwerke Ag | Bispezifische und oligospezifische, mono- und oligovalente antikoerperkonstrukte, ihre herstellung und verwendung |
ES2108048T3 (es) | 1990-08-29 | 1997-12-16 | Genpharm Int | Produccion y utilizacion de animales inferiores transgenicos capaces de producir anticuerpos heterologos. |
ATE297465T1 (de) | 1991-11-25 | 2005-06-15 | Enzon Inc | Verfahren zur herstellung von multivalenten antigenbindenden proteinen |
CA2124967C (en) | 1991-12-17 | 2008-04-08 | Nils Lonberg | Transgenic non-human animals capable of producing heterologous antibodies |
CA2140638C (en) | 1992-07-24 | 2010-05-04 | Raju Kucherlapati | Generation of xenogeneic antibodies |
US5648267A (en) | 1992-11-13 | 1997-07-15 | Idec Pharmaceuticals Corporation | Impaired dominant selectable marker sequence and intronic insertion strategies for enhancement of expression of gene product and expression vector systems comprising same |
CA2161351C (en) | 1993-04-26 | 2010-12-21 | Nils Lonberg | Transgenic non-human animals capable of producing heterologous antibodies |
EP0770628B9 (en) | 1994-07-13 | 2007-02-28 | Chugai Seiyaku Kabushiki Kaisha | Reconstituted human antibody against human interleukin-8 |
US20030180784A1 (en) | 1997-04-04 | 2003-09-25 | Millennium Pharmaceuticals, Inc. | Novel human Delta3 compositions and therapeutic and diagnostic uses therefor |
US20060122373A1 (en) | 1997-04-04 | 2006-06-08 | Millennium Pharmaceuticals, Inc. | Delta3, FTHMA-070, Tango85, Tango77, SPOIL,NEOKINE, Tango129 and integrin alpha subunit protein and nucleic acid molecules and uses thereof |
EP0972041B2 (en) | 1997-04-04 | 2017-01-18 | Millennium Pharmaceuticals, Inc. | Novel human delta3 compositions and therapeutic and diagnostic uses therefor |
JP4139508B2 (ja) | 1998-02-19 | 2008-08-27 | 旭化成株式会社 | ヒトデルター3 |
JP4332581B2 (ja) | 1998-02-19 | 2009-09-16 | 旭化成株式会社 | ヒトデルタ−3 |
PT1071700E (pt) | 1998-04-20 | 2010-04-23 | Glycart Biotechnology Ag | Modificação por glicosilação de anticorpos para melhorar a citotoxicidade celular dependente de anticorpos |
JP2002540763A (ja) | 1999-02-10 | 2002-12-03 | ヒューマン ジノーム サイエンシーズ, インコーポレイテッド | 33個のヒト分泌タンパク質 |
PT1914244E (pt) | 1999-04-09 | 2013-07-26 | Kyowa Hakko Kirin Co Ltd | Processo para regular a actividade de moléculas funcionais sob o ponto de vista imunológico |
JP2003507029A (ja) | 1999-08-19 | 2003-02-25 | カイロン コーポレイション | Notchレセプターリガンドおよびその使用 |
US6436703B1 (en) | 2000-03-31 | 2002-08-20 | Hyseq, Inc. | Nucleic acids and polypeptides |
AU2001280471A1 (en) | 2000-08-11 | 2002-02-25 | Eli Lilly And Company | Novel secreted proteins and their uses |
CA2785941C (en) | 2000-10-06 | 2017-01-10 | Kyowa Hakko Kirin Co., Ltd. | Antibody composition-producing cell |
WO2002079255A1 (en) | 2001-04-02 | 2002-10-10 | Idec Pharmaceuticals Corporation | RECOMBINANT ANTIBODIES COEXPRESSED WITH GnTIII |
AU2002330039A1 (en) | 2001-09-17 | 2003-04-01 | Eos Biotechnology, Inc. | Methods of diagnosis of cancer compositions and methods of screening for modulators of cancer |
US20050137130A1 (en) | 2001-11-14 | 2005-06-23 | Bodmer Mark W. | Medical treatment |
JP3991280B2 (ja) | 2002-06-05 | 2007-10-17 | 中外製薬株式会社 | 抗体作製方法 |
US20070224201A1 (en) | 2002-10-02 | 2007-09-27 | Genentech, Inc. | Compositions and methods for the diagnosis and treatment of tumor |
US20040115204A1 (en) * | 2002-12-11 | 2004-06-17 | Fanger Gary R. | Antibodies to treat cancer |
DE602004028249D1 (de) | 2003-06-18 | 2010-09-02 | Chugai Pharmaceutical Co Ltd | Fucosetransporter |
US20050175619A1 (en) | 2004-02-05 | 2005-08-11 | Robert Duffy | Methods of producing antibody conjugates |
RU2008129028A (ru) * | 2005-12-16 | 2010-01-27 | Дженентек, Инк. (Us) | Способ диагностики, прогнозировния и лечения глиомы |
EP2216339A1 (en) * | 2006-01-16 | 2010-08-11 | Compugen Ltd. | Novel nucleotide and amino acid sequences, and methods of use thereof for diagnosis |
EP2078731A4 (en) | 2006-10-20 | 2012-08-01 | Forerunner Pharma Res Co Ltd | PHARMACEUTICAL COMPOSITION COMPRISING ANTI-HB-EGF ANTIBODY AS ACTIVE INGREDIENT |
WO2008093688A1 (ja) | 2007-01-30 | 2008-08-07 | Forerunner Pharma Research Co., Ltd. | キメラFcγレセプター及び該レセプターを用いたADCC活性測定方法 |
WO2009124931A2 (en) | 2008-04-07 | 2009-10-15 | Ablynx Nv | Amino acid sequences directed against the notch pathways and uses thereof |
JP4787295B2 (ja) | 2008-07-14 | 2011-10-05 | 株式会社トープラ | 高強度セルフフォーミングねじによるねじ締結構造体 |
RS62387B1 (sr) | 2010-01-29 | 2021-10-29 | Chugai Pharmaceutical Co Ltd | Anti-dll3 antitelo |
EP3093293A1 (en) * | 2012-02-24 | 2016-11-16 | Stemcentrx, Inc. | Anti dll3 antibodies and methods of use thereof |
KR20170008202A (ko) * | 2014-02-21 | 2017-01-23 | 애브비 스템센트알엑스 엘엘씨 | 흑색종에 사용하기 위한 항-dll3 항체 및 약물 접합체 |
TW202346349A (zh) | 2015-07-31 | 2023-12-01 | 德商安美基研究(慕尼黑)公司 | Dll3及cd3抗體構築體 |
-
2011
- 2011-01-28 RS RS20211159A patent/RS62387B1/sr unknown
- 2011-01-28 HU HUE18156974A patent/HUE056313T2/hu unknown
- 2011-01-28 HU HUE11736812A patent/HUE038962T2/hu unknown
- 2011-01-28 EP EP18156974.0A patent/EP3342786B1/en active Active
- 2011-01-28 DK DK11736812.6T patent/DK2530091T3/en active
- 2011-01-28 DK DK18156974.0T patent/DK3342786T3/da active
- 2011-01-28 SI SI201131477T patent/SI2530091T1/en unknown
- 2011-01-28 ES ES11736812.6T patent/ES2674420T3/es active Active
- 2011-01-28 PL PL18156974T patent/PL3342786T3/pl unknown
- 2011-01-28 US US13/575,861 patent/US9127071B2/en active Active
- 2011-01-28 ES ES18156974T patent/ES2889932T3/es active Active
- 2011-01-28 JP JP2011551775A patent/JP5918540B2/ja active Active
- 2011-01-28 LT LTEP18156974.0T patent/LT3342786T/lt unknown
- 2011-01-28 EP EP21171265.8A patent/EP3907242A1/en active Pending
- 2011-01-28 LT LTEP11736812.6T patent/LT2530091T/lt unknown
- 2011-01-28 PT PT117368126T patent/PT2530091T/pt unknown
- 2011-01-28 WO PCT/JP2011/000485 patent/WO2011093097A1/ja active Application Filing
- 2011-01-28 TR TR2018/06936T patent/TR201806936T4/tr unknown
- 2011-01-28 PT PT181569740T patent/PT3342786T/pt unknown
- 2011-01-28 RS RS20180696A patent/RS57412B1/sr unknown
- 2011-01-28 PL PL11736812T patent/PL2530091T3/pl unknown
- 2011-01-28 EP EP11736812.6A patent/EP2530091B1/en active Active
- 2011-01-28 HR HRP20211444TT patent/HRP20211444T1/hr unknown
- 2011-01-28 SI SI201131999T patent/SI3342786T1/sl unknown
-
2015
- 2015-09-04 US US14/846,135 patent/US11111311B2/en active Active
-
2018
- 2018-06-19 HR HRP20180952TT patent/HRP20180952T1/hr unknown
-
2021
- 2021-08-19 US US17/406,504 patent/US20210380715A1/en active Pending
Also Published As
Publication number | Publication date |
---|---|
TR201806936T4 (tr) | 2018-06-21 |
EP3342786A1 (en) | 2018-07-04 |
ES2889932T3 (es) | 2022-01-14 |
US20210380715A1 (en) | 2021-12-09 |
WO2011093097A1 (ja) | 2011-08-04 |
JPWO2011093097A1 (ja) | 2013-05-30 |
SI2530091T1 (en) | 2018-06-29 |
US20150368355A1 (en) | 2015-12-24 |
HUE038962T2 (hu) | 2018-12-28 |
SI3342786T1 (sl) | 2022-01-31 |
PT2530091T (pt) | 2018-05-17 |
PT3342786T (pt) | 2021-09-24 |
DK2530091T3 (en) | 2018-05-28 |
EP3342786B1 (en) | 2021-06-23 |
PL3342786T3 (pl) | 2021-12-20 |
ES2674420T3 (es) | 2018-06-29 |
EP2530091B1 (en) | 2018-04-04 |
LT2530091T (lt) | 2018-06-11 |
HRP20211444T1 (hr) | 2021-12-24 |
DK3342786T3 (en) | 2021-09-27 |
US9127071B2 (en) | 2015-09-08 |
EP3907242A1 (en) | 2021-11-10 |
EP2530091A4 (en) | 2013-07-10 |
LT3342786T (lt) | 2021-10-25 |
HRP20180952T1 (hr) | 2018-07-27 |
US20160244530A2 (en) | 2016-08-25 |
EP2530091A1 (en) | 2012-12-05 |
PL2530091T3 (pl) | 2018-08-31 |
HUE056313T2 (hu) | 2022-02-28 |
US11111311B2 (en) | 2021-09-07 |
RS62387B1 (sr) | 2021-10-29 |
US20120328624A1 (en) | 2012-12-27 |
JP5918540B2 (ja) | 2016-05-18 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
HRP20180952T1 (hr) | Anti-dll3 antitijelo | |
HRP20180640T1 (hr) | Anti-b7-h3 antitijelo | |
IL259826A (en) | Anti-alphabetatisiar antibody | |
HUE040213T2 (hu) | Anti-TIM antitest | |
ZA201209004B (en) | Anti-fgfr2 antibodies | |
PL2616489T3 (pl) | Przeciwciało anty-huTNFR1 | |
GB201000467D0 (en) | Antibodies | |
IL221371A0 (en) | Anti-lrp6 antibodies | |
EP2543730A4 (en) | VARIANT OF A CONSTANT ANTIBODY REGION | |
IL225667A0 (en) | A new antigen | |
HK1194388A1 (zh) | 抗缺刻蛋白 抗體 | |
PT2603528T (pt) | Anticorpos glicosilados em fab | |
GB201020738D0 (en) | Antibodies | |
GB201002238D0 (en) | Antibodies | |
ZA201302459B (en) | Antibodies | |
GB201007957D0 (en) | Antibody | |
EP2769988A4 (en) | ANTI-GAP43 ANTIBODY | |
GB201017780D0 (en) | Antibody | |
GB201020751D0 (en) | Antibodies | |
GB201005062D0 (en) | Antibodies |